As of November 7, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Satellos Bioscience Inc. The largest reported stake is Qiming U.S. Healthcare Fund III, L.P.'s, at 8.3%. 2 filings are on record since May 12, 2026 (Schedule 13G, May 12, 2026).
Sell to companies like Satellos Bioscience Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Satellos Bioscience Inc. has 2 Schedule 13D or 13G filings on record since 2026-05-12. 2 holders' latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Qiming U.S. Healthcare Fund III, L.P. | 8.3% | 1,725,247 | SCHEDULE 13G, 2026-05-12 | 2026-03-31 |
| 7.35% | 1,133,401 | SCHEDULE 13G, 2026-05-15 | 2026-02-06 |
Holding shares or following this stake? See who's behind Satellos Bioscience Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Satellos Bioscience Inc. and the records around it.
Satellos Bioscience Inc. elsewhere on the record
Watch Satellos Bioscience Inc.
Get an email when Satellos Bioscience Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Satellos Bioscience Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Satellos Bioscience Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Satellos Bioscience Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Qiming U.S. Healthcare Fund III, L.P. | 0 | 1,725,247 | 0 | 1,725,247 | SCHEDULE 13G, 2026-05-12 |
| Qiming U.S. Healthcare GP III, LLC | 0 | 1,725,247 | 0 | 1,725,247 | SCHEDULE 13G, 2026-05-12 |
| Mark McDade | 0 | 1,725,247 | 0 | 1,725,247 | SCHEDULE 13G, 2026-05-12 |
| Gary E Rieschel | 0 | 1,725,247 | 0 | 1,725,247 | SCHEDULE 13G, 2026-05-12 |
| Brian Matthew Bloom | 126,874 | 1,010,167 | 126,874 | 1,137,041 | SCHEDULE 13G, 2026-05-15 |
| Bloom Burton & Co. Inc. | 0 | 1,010,167 | 0 | 1,010,167 | SCHEDULE 13G, 2026-05-15 |
| Jolyon David Burton | 0 | 1,010,167 | 0 | 1,010,167 | SCHEDULE 13G, 2026-05-15 |
The latest filing identifies Satellos Bioscience Inc. by CUSIP 80401L803 and gives its principal executive office as Royal Bank Plaza, South Tower, 200 Bay Street, Suite 2800, Canada (SCHEDULE 13G, 2026-05-15).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the Shares beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.Qiming U.S. Healthcare Fund III, L.P., SCHEDULE 13G, 2026-05-12
7.35% Based on the quotient obtained by dividing (a) the aggregate number of ordinary shares beneficially owned by the Reporting Person as set forth in Row 9 by (b) the sum of (i) 15,458,903 ordinary shares outstanding as of February 5, 2026 as reported by the Issuer in their Rule 424(b)(4) Prospectus and (ii) 3,641 common shares issuable upon exercise of options beneficially owned by the Reporting Person.Brian Matthew Bloom, SCHEDULE 13G, 2026-05-15
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-05-12 | Qiming U.S. Healthcare Fund III, L.P. | 8.3% | SCHEDULE 13G |
| 2026-05-15 | Brian Matthew Bloom | 7.35% | SCHEDULE 13G |
Questions about who owns Satellos Bioscience Inc.
Who owns Satellos Bioscience Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Satellos Bioscience Inc.: Qiming U.S. Healthcare Fund III, L.P. (8.3%, Schedule 13G, filed 2026-05-12) and Brian Matthew Bloom (7.35%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Satellos Bioscience Inc.?
By the share each holder's latest filing reports, the largest holders of Satellos Bioscience Inc. on this page are Qiming U.S. Healthcare Fund III, L.P. (8.3%) and Brian Matthew Bloom (7.35%).
When did Qiming U.S. Healthcare Fund III, L.P. buy into Satellos Bioscience Inc.?
The filings give report dates, not purchase dates. The earliest filing from Qiming U.S. Healthcare Fund III, L.P. on this page is the Schedule 13G, filed 2026-05-12, reporting 8.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Satellos Bioscience Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 3, 2025 | Form D, private offering | $25.02M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Satellos Bioscience Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.